

13th September, 2017

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

To,
Dy. General Manager,
Corporate Relationship Department,
BSE Limited,
P. J. Tower,
Mumbai – 400 001

Dear Sir,

Sub: Outcome of Board Meeting

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We wish to inform that the Board of Director at its meeting held on Wednesday, 13th September, 2017 (commenced at 1.30 P.M. and concluded at 3.40 P.M.) at its Registered Office, have inter-alia considered and approved the following business:

1. Unaudited Financial Results for 01st quarter ended 30th June, 2017 pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
2. Limited Review Report by the Statutory Auditors on Unaudited Financial Results for the 01st quarter ended 30th June, 2017.

The above information is also available on Company's website www.adinathbio.com and on the Stock exchange website: www.cse-india.com and www.bseindia.com.

Please acknowledge the receipt.

Yours faithfully,
For Adinath Bio-Labs Limited

Abhishek Jain
Abhishek Kumar Jain
Whole time Director
DIN: 00054582



Encl.: As Above

Email: investors@adinathbio.com
<http://www.adinathbio.com>


4, N. S. Road, 1st Floor, Kolkata – 700 001
Telephone: +91-33-22315718

Statement of Standalone Unaudited Financial Results for the Quarter ended on 30th June 2017			
Sl. No.	Particulars	Quarter Ended	
		30th June, 2017	30th June, 2016
		Unaudited	Unaudited (refer Note No. 4)
I	Revenue		
	Revenue from Operations	11,22,670	19,10,570
	Other Income	-	-
	Total Revenue (I)	11,22,670	19,10,570
II	EXPENSES		
	Employee Benefits Expense	3,53,354	6,15,285
	Depreciation and Amortisation Expense	2,12,015	2,86,195
	Finance Cost	-	-
	Other Expenses	5,29,398	8,91,033
	Total Expenses (II)	10,94,767	17,92,513
III	Profit / (Loss) before Taxation (I-II)	27,903	1,18,057
IV	Tax Expenses		
	Current Tax	-	-
	Deferred Tax	-	-
	Total Tax Expenses	-	-
V	Profit / (Loss) for the year (III - IV)	27,903	1,18,057
VI	Other Comprehensive Income / (Loss)	-	-
VII	Total Comprehensive Income / (Loss) (V +/- VI)	27,903	1,18,057
VIII	Paidup Equity Share Capital (FV of Re. 1/- each)	22,07,42,560	22,07,42,560
IX	Earning Per Share (FV of Re. 1/- each)		
a)	Basic (not annualised) (in Rs.)	0.00	0.00
b)	Diluted (not annualised) (in Rs.)	0.00	0.00

Notes:

- The above Unaudited Financial results have been reviewed by the Audit committee at their meeting held on 12th September 2017 and adopted by the Board of Directors at their meeting held on 13th September, 2017.
- The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Beginning with 01st April, 2017, the company has for the first time adopted Ind AS with the transition date of 01st April, 2016. The financial results are made available on the company's website www.adinathbio.com. Financial Results of all the periods presented have been prepared in accordance with the recognition and the measurement principles of IND AS - 34 (Interim Financial Reporting).
- The company is engaged in the business of Trading in Commodities and it's allied products and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- The Ind AS Compliant Financial Result pertaining to period 30th June, 2016 has not been subjected to Limited Review or audit. However, the management has exercised necessary due diligence to ensure that such results provides true and fair view of affairs.
- Provisions for taxations will be made at the end of the year.
- The statement does not contain Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017 as the same is not mandatory as per SEBI circular CIR/CFD/FAC/62/2016 dated 05th July, 2016.

Date: 13th September, 2017
Place: Kolkata



By order of the Board
For Adinath Bio-Labs Limited

Abhishek Kumar Jain

Abhishek Kumar Jain
Whole -Time Director
DIN No.: 00054582

Email:investors@adinathbio.com
http://www.adinathbio.com

4, N. S. Road, 1st Floor, Kolkata – 700 001
Telephone:+91-33-22315718

Limited Review Report

To,
The Board of Directors,
M/s. Adinath Bio-labs Limited

1. We have reviewed the accompanying statement of unaudited financial results of M/s. Adinath Bio-labs Limited ("the Company") for the quarter ended June 30, 2017 together with the notes thereon (the "Statement"). The statement has been prepared by the Company pursuant to the requirements of Regulations 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulation, 2015") read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initialled by us for identification purpose.
2. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Further, the Management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company's opening Unaudited Balance Sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind-AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an opinion.
4. We were neither engaged to review, nor have we reviewed the comparative figures including the reconciliation to the Total Comprehensive Income for the quarter ended on June 30, 2016 and accordingly, we do not express any conclusion on the results in the Statement for the quarter ended June 30, 2016. As set out in Note 4 to the Statement, these figures have been furnished by the Management.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 read with SEBI circular dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not qualified in respect of these matters.

For, Mohindra Arora & Co.
Chartered Accountants
Firm registration No:00655176

Place : Mumbai
Date : September 12, 2017



Ashok Katial
Partner
Membership No: 09096